Chiesi Farmaceutici agrees to acquire KalVista Pharmaceuticals for $1.9 billion

7 articles · Updated · Bloomberg · Apr 29

The Italian company will launch a tender offer to buy all KalVista shares at $27 per share in cash.
This marks Chiesi’s largest acquisition to date and was approved by the boards of both companies.
The deal aims to expand Chiesi’s rare immunology portfolio and strengthens its presence in the US pharmaceutical market.

Is Chiesi's big bet a sign that oral drugs will dethrone injectables in rare diseases?

With a $1.9B price tag, can an oral HAE drug alone deliver the returns Chiesi needs?

Can a pharma giant truly acquire a biotech's patient-centric 'rare disease mindset' after a merger?

With the pharma patent cliff looming, are billion-dollar deals for niche assets the new path to survival?

What makes an oral HAE treatment worth nearly $2 billion in today's pharma market?